Clinical trials: nAMD
nAMD
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
The goal of this clinical trial is to evaluate the safety and efficacy of IVB103 injection in subjects with nAMD.
- Trial name
- NCT06737354
- Testing
- IVB103 Injection（Low dose）, IVB103 Injection（Intermediate dose）, IVB103 Injection（High dose）
- Where
- China
- Volunteers
- 18 people
- Sponsor
- InnoVec Biotherapeutics Inc.
Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related…
- Trial name
- NCT06470373
- Testing
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Where
- 7 sites in United States
- Volunteers
- 434 people
- Sponsor
- Rophibio, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
This study is a prospective, observational, non-interventional, multicenter, open-label, single arm study in patients being treated for nAMD with brolucizumab in Portugal.
- Trial name
- BLUESKY-PT (NCT04764656)
- Testing
- Brolucizumab
- Where
- 11 sites in Portugal
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration(nAMD)
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in AMD.
- Trial name
- NCT06031727
- Testing
- HG202
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)
This is a research plan from the University of Munich (LMU) that aims to study how the use of AI reports can impact ophthalmologists' decisions regarding treatment for patients with neovascular age-related macular degeneration…
- Trial name
- LMU ASSIST (NCT06817915)
- Testing
- AI assisted assessment of SD-OCT scans
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johannes Schiefelbein
Age-Related Macular Degeneration, NAMD
Targeted Fluorescence Imaging in AMD
Rationale: To track performance of intravitreal distribution of anti-VEGF-A (Bevazicumab-800CW) and provide information about neovascularization and inflammation in Age-Related Macular Degeneration (AMD), thereby predicting…
- Trial name
- LEAF (NCT05262244)
- Testing
- Bevacizumab-IRDye800CW
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-Related Macular Degeneration (nAMD)
Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial
Age-related macular degeneration (AMD) leads to severe and irreversible vision loss, while neovascular AMD (nAMD) accounts for 80-90% of AMD blindness.
- Trial name
- BRIGHT (NCT06623279)
- Testing
- HG202
- Volunteers
- 15 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Neovascular Age-related Macular Degeneration (nAMD)
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients…
- Trial name
- NCT06487039
- Testing
- EB-203
- Where
- 5 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- EyebioKorea, Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up…
- Trial name
- SHASTA (NCT04746963)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- AsclepiX Therapeutics, Inc.
To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD
To evaluate the safety and tolerability of intravitreal injection of LX109 in patients with nAMD.
- Trial name
- NCT06022744
- Testing
- LX109
- Volunteers
- 12 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
- Trial name
- NCT05282004
- Testing
- SOK583A1
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sandoz
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
- Trial name
- NCT05161806
- Testing
- SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sandoz